Literature DB >> 7532676

FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells.

L Venkataraman1, S J Burakoff, R Sen.   

Abstract

Stimulation of B and T cells via the antigen receptor, by phorbol ester or by phorbol ester and ionomycin, leads to nuclear translocation of the inducible transcription factor NF-kappa B, comprising the p50 and p65 rel-related polypeptides. In this report we show that c-rel is a component of the antigen receptor-induced kappa B binding proteins in both B and T cells. Whereas NF-kappa B can be induced by phorbol ester alone, optimal induction of c-rel requires stimulation by both phorbol ester and ionomycin, the dual signal that is necessary for proliferation of untransformed lymphocytes. Furthermore, c-rel induction is blocked by the immunosuppressive drug FK506 that is known to inhibit B and T cell activation. c-rel-dependent transactivation of the interleukin-2 receptor alpha chain (IL-2R alpha) promoter is augmented by coexpression of calcineurin, suggesting the involvement of a calcineurin-dependent intracellular pathway. Our results identify c-rel as a target of immunosuppressive agents and illustrate the similarity of activation pathways in both B and T cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532676      PMCID: PMC2191924          DOI: 10.1084/jem.181.3.1091

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

Review 1.  The inhibitory ankyrin and activator Rel proteins.

Authors:  G P Nolan; D Baltimore
Journal:  Curr Opin Genet Dev       Date:  1992-04       Impact factor: 5.578

Review 2.  NF-kappa B and Rel: participants in a multiform transcriptional regulatory system.

Authors:  M Grilli; J J Chiu; M J Lenardo
Journal:  Int Rev Cytol       Date:  1993

3.  Protein kinase C activation blocks anti-IgM-mediated signaling BAL17 B lymphoma cells.

Authors:  J Mizuguchi; Y Y Ji; H Nakabayaschi; K P Huang; M A Beaven; T Chused; W E Paul
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

4.  NF-AT components define a family of transcription factors targeted in T-cell activation.

Authors:  J P Northrop; S N Ho; L Chen; D J Thomas; L A Timmerman; G P Nolan; A Admon; G R Crabtree
Journal:  Nature       Date:  1994-06-09       Impact factor: 49.962

5.  Isolation of the cyclosporin-sensitive T cell transcription factor NFATp.

Authors:  P G McCaffrey; C Luo; T K Kerppola; J Jain; T M Badalian; A M Ho; E Burgeon; W S Lane; J N Lambert; T Curran
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

6.  Induction of CREB activity via the surface Ig receptor of B cells.

Authors:  H Xie; T C Chiles; T L Rothstein
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

7.  Cyclosporin A sensitivity of the NF-kappa B site of the IL2R alpha promoter in untransformed murine T cells.

Authors:  P G McCaffrey; P K Kim; V E Valge-Archer; R Sen; A Rao
Journal:  Nucleic Acids Res       Date:  1994-06-11       Impact factor: 16.971

8.  Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human c-Rel.

Authors:  T H Tan; G P Huang; A Sica; P Ghosh; H A Young; D L Longo; N R Rice
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

9.  Cyclosporin-A sensitive induction of NF-AT in murine B cells.

Authors:  L Venkataraman; D A Francis; Z Wang; J Liu; T L Rothstein; R Sen
Journal:  Immunity       Date:  1994-06       Impact factor: 31.745

10.  Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.

Authors:  B Frantz; E C Nordby; G Bren; N Steffan; C V Paya; R L Kincaid; M J Tocci; S J O'Keefe; E A O'Neill
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  19 in total

Review 1.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

Authors:  Y Yamamoto; R B Gaynor
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 2.  NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions.

Authors:  Jorge Caamaño; Christopher A Hunter
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

Review 3.  Roles of the NF-kappaB pathway in lymphocyte development and function.

Authors:  Steve Gerondakis; Ulrich Siebenlist
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-23       Impact factor: 10.005

Review 4.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

5.  Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB.

Authors:  K Kalli; C Huntoon; M Bell; D J McKean
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

6.  Naive CD4 T cells from aged mice show enhanced death upon primary activation.

Authors:  Hamid Mattoo; Matthew Faulkner; Usha Kandpal; Rituparna Das; Virginia Lewis; Anna George; Satyajit Rath; Jeannine M Durdik; Vineeta Bal
Journal:  Int Immunol       Date:  2009-09-11       Impact factor: 4.823

7.  The c-Rel Transcription Factor in Development and Disease.

Authors:  Thomas D Gilmore; Steve Gerondakis
Journal:  Genes Cancer       Date:  2011-07

Review 8.  Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase.

Authors:  W N Khan
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

9.  c-Rel is required for the development of thymic Foxp3+ CD4 regulatory T cells.

Authors:  Iwao Isomura; Stephanie Palmer; Raelene J Grumont; Karen Bunting; Gerard Hoyne; Nancy Wilkinson; Ashish Banerjee; Anna Proietto; Raffi Gugasyan; Li Wu; Wu Li; Alice McNally; Raymond J Steptoe; Ranjeny Thomas; M Frances Shannon; Steve Gerondakis
Journal:  J Exp Med       Date:  2009-12-07       Impact factor: 14.307

10.  Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor.

Authors:  S Gerondakis; A Strasser; D Metcalf; G Grigoriadis; J Y Scheerlinck; R J Grumont
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.